2006-07-01
Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples
Publication
Publication
Leukemia , Volume 20 - Issue 7 p. 1217- 1220
In acute myeloid leukemia (AML), activating mutations in the fms-like tyrosine kinase 3 (FLT3) gene predict poor prognosis. We determined FLT3 internal tandem duplications (FLT3/ITD) and D835 point mutations in paired initial and relapse samples from 80 pediatric and adult AML patients. One D835 point mutation was found in an initial pediatric AML sample. Fms-like tyrosine kinase 3/ITDs were present in 21 initial and 22 relapse samples (26.3 and 27.5%, respectively). Interestingly, FLT3/ ITD positivity was related to a significantly shorter time to relapse, most pronounced when the ITD-positive status was found at relapse (P<0.001). However, FLT3/ITD status changed between diagnosis and relapse in 14 cases. In four patients, the FLT3/ITD became undetectable at relapse in five patients FLT3/ITDs were only detected at relapse, and in five patients the length or number of FLT3/ITDs changed. Gain of FLT3/ ITDs may suggest oligoclonality with selective outgrowth of the FLT3/ ITD-positive clone, whereas losses may reflect ITDs in the more mature leukemic cells rather than in the leukemic stem cell, or, alternatively, that other genetic aberrations provided a greater selective advantage. Studying FLT3/ITD kinetics in minimal residual disease setting may provide some answers for the changes we observed. Fms-like tyrosine kinase 3/ITD is a relevant marker for prognosis, and remains an important target for therapeutic inhibition.
| Additional Metadata | |
|---|---|
| , , | |
| doi.org/10.1038/sj.leu.2404246, hdl.handle.net/1765/73075 | |
| Leukemia | |
| Organisation | Department of Immunology |
|
Cloos, J., Goemans, B., Hess, C., van Oostveen, J., Waisfisz, Q., Corthals, S., de Lange, D., Boeckx, N., Hählen, K., Reinhardt, D., Creutzig, U., Schuurhuis, G. J., Zwaan, M.& Kaspers, G. (2006). Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia, 20(7), 1217–1220.https://doi.org/10.1038/sj.leu.2404246 |
|